Other Events ·
CMS reverses billing changes for non-invasive bone growth stimulators after FDA reclassification
OFIXOrthofix Medical Inc.
Orthofix Medical Inc. expects average Medicare reimbursement rates for non-invasive bone growth stimulators (HCPCS codes E0747, E0748, and E0760) to return to levels in effect prior to May 18, 2026. This follows CMS guidance issued on July 1, 2026, which reversed previous billing and fee schedule changes triggered by the FDA reclassification of these devices from Class III to Class II. Orthofix Medical Inc. operates in the medical device industry, providing bone growth stimulators and related orthopedic solutions.